logo
Book a meeting
CHO Plus

Cho Plus

Biotechnology, 329 Oyster Point BLVD, South San Francisco​, , ​, California, 94080, United States, 1-10 Employees

cho-plus.com

  • facebook
  • LinkedIn

phone no Phone Number: 84********

Who is CHO PLUS

CHO Plus is creating regulatory compliant genetically engineered mammalian cells to be used by biopharmaceutical companies for therapeutic protein manufacturing. Early proof of concept ex...

Read More

lock icon Get Full Access
map
  • 329 Oyster Point BLVD, South San Francisco​, California, 94080​, United States Headquarters: 329 Oyster Point BLVD, South San Francisco​, California, 94080​, United States
  • 2014 Date Founded: 2014
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies
  • Larry Forman CEO:   Larry Forman

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from CHO PLUS

CHO Plus Org Chart and Mapping

Larry Forman

Larry Forman

Founder, CEO

Employees
James Dal Santo

James Dal Santo

Research Assistant

Nancy Hilgert

Nancy Hilgert

Medical Transcriptionist

Kathy N

Kathy N

Associate Director

Rose Val

Rose Val

Business Office Manager

See Full Org Chart arrow
email-formate-icon
View Email Formats for CHO Plus
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding CHO Plus

Answer: CHO Plus's headquarters are located at 329 Oyster Point BLVD, South San Francisco​, , ​, California, 94080, United States

Answer: CHO Plus's phone number is 84********

Answer: CHO Plus's official website is https://cho-plus.com

Answer: CHO Plus's revenue is $1 Million to $5 Million

Answer: CHO Plus's SIC: 8731

Answer: CHO Plus has 1-10 employees

Answer: CHO Plus is in Biotechnology

Answer: CHO Plus contact info: Phone number: 84******** Website: https://cho-plus.com

Answer: CHO Plus is creating regulatory compliant genetically engineered mammalian cells to be used by biopharmaceutical companies for therapeutic protein manufacturing. Early proof of concept experiments demonstrate CHO Plus cells to be 4.5-fold more productive than parent cells in model system. The CHO Plus approach includes patented methods for genetically engineering mammalian cells; proprietary and patented targeted transfection technology; and efficient clone screening technology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access